HOME >> BIOLOGY >> NEWS
Joslin Diabetes Center scientists find 'brown fat cells' hold clues for possible obesity treatments

BOSTON -- Joslin Diabetes Center scientists have discovered a group of genes that govern the genesis of calorie-burning fat cells. This discovery may lead to novel ways to treat obesity in humans.

"With obesity at epidemic levels, finding new ways to treat it is one of medicine's holy grails," said C. Ronald Kahn, M.D., President of Joslin Diabetes Center, the Mary K. Iacocca Professor of Medicine at Harvard Medical School (HMS), and principal investigator of the study that appears in the June edition of the journal Nature Cell Biology. In laboratory studies of mouse cells, his research team identified genes that govern how precursor cells give rise to mature brown fat cells.

There are two main types of fat cells in the body -- white and brown. White fat cells are the "conventional" form of fat that we all recognize. They are designed to store energy for use in times of need. Chocked full of lipid droplets, these big cells accumulate under the skin and around internal organs.

By contrast, the main role of brown fat cells is to burn energy and generate heat. They contain small lipid droplets tucked between tiny energy factories called mitochondria. In mice, brown fat cells are found throughout the body and are present during the entire life cycle. In humans, they are principally found in the neck area of newborns, helping their tiny bodies generate heat. Brown fat cells largely disappear by adulthood, but their precursors still remain in the body, lodged in white-fat depots.

Because brown fat cells burn calories, Joslin scientists theorized that finding ways to encourage the development of brown fat might be good for treating obesity. In previous research, the scientists were among the first to develop cell lines of precursor cells that give rise to brown fat cells. "We used those cell lines to study how insulin affects the conversion of fat precursors, or preadipocytes, into mature brown adipocytes," said Yu-Hu
'"/>

Contact: Marjorie Dwyer
marjorie.dwyer@joslin.harvard.edu
617-732-2415
Joslin Diabetes Center
25-May-2005


Page: 1 2 3

Related biology news :

1. Joslin study indicates insulin receptors play a critical role in promoting islet growth
2. Joslin researchers discover a surprising culprit in the search for causes of diabetic birth defects
3. Joslin study reveals how a specific fat type can protect against weight gain and diabetes
4. Joslin discovers protein that causes blood vessel leakage and swelling with diabetic retinopathy
5. Joslin-led study uncovers role of appetite hormone MCH in insulin production
6. Joslin Diabetes Center study examines insulin pump therapy in adolescents
7. Joslin Diabetes Center in Boston establishes first affiliate in Canada
8. Walgreens and Joslin Diabetes Center form broad alliance to improve diabetes outcomes
9. Joslin awards Victory Medal to New York man living 75 years with type 1 diabetes
10. Joslins new book demystifies nutrition and meal planning for people with diabetes
11. Joslin study refutes recent report that bone marrow can replenish female oocytes

Post Your Comments:
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
(Date:7/29/2015)... Station, TX (PRWEB) , ... July 29, 2015 ... ... POD® designer, manufacturer and supplier, announces the launch of their 2nd generation cell ... to the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... 29, 2015  AmnioChor Inc., an early stage biotech ... pleased to announce that the Musculoskeletal Transplant Foundation of ... invest in their seed round of development of the ... capabilities. AmnioChor,s technology allows cryopreservation of ... stem cells living within those tissues. Amnion is a ...
(Date:7/29/2015)...  Indivior PLC (LON: INDV) today announced that the ... accepted and received Priority Review by the U.S. Food ... overdose. This naloxone nasal spray comes as a pre-filled ... into the nasal mucosa. 1 The device has ... be better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
Cached News: